Atossa Therapeutics Presents Promising Study Results
Atossa Therapeutics, Inc. (NASDAQ: ATOS), a leading clinical-stage biopharmaceutical entity focused on innovative breast cancer therapies, recently shared impactful findings from its Phase 2 Endocrine Optimization Pilot sub-study carried out within the I-SPY 2 TRIAL. This study specifically evaluated the effects of low-dose (Z)-endoxifen, administered at 10 mg daily, among 20 women diagnosed with stage II/III estrogen-receptor-positive (ER+), HER2-negative breast cancer.
Positive Outcomes from the Study
The results demonstrated significant achievements, indicating the feasibility of the treatment approach. Notably, 95 percent of participants managed to complete at least 75 percent of their planned dosing schedule, outperforming the initially established threshold.
Rapid Response Observed
Within three weeks of treatment, the median Ki-67, a crucial marker for tumor proliferation, showed a drastic reduction from 10.5 percent to 5 percent. An impressive 65 percent of the patients reached a Ki-67 level of 10 percent or below, with this suppression sustained through surgery.
Substantial Tumor Shrinkage
Moreover, tumor measurements reflected remarkable efficacy. The median functional tumor volume (FTV) showed a decrease of 77.7 percent from baseline to surgery, alongside a significant reduction of 36.8 percent in the longest tumor diameter observed prior to surgery. These imaging results speak volumes about the effectiveness of (Z)-endoxifen.
Safety Profile Highlights
On the safety front, the treatment was well tolerated among participants. Predominantly Grade 1 adverse events like vasomotor symptoms (hot flushes) and fatigue surfaced, with only three Grade 3 events reported that were unrelated to the medication. Notably, there were no severe Grade 4 or Grade 5 complications.
Pathologic Insights
Interestingly, no participants achieved a pathologic complete response (pCR). The residual cancer burden indicated moderate to extensive disease, aligning with earlier findings demonstrating that higher doses of (Z)-endoxifen are necessary for substantial pathologic clearance.
What This Means for Future Research
Dr. Steven Quay, M.D., Ph.D., President and CEO of Atossa Therapeutics, emphasized, "These results reveal that even at a low dosage, (Z)-endoxifen exhibits bioactivity, effectively reducing tumor proliferation and size, while maintaining an excellent safety record. Our focus will now shift to evaluating higher doses in ongoing trials to enhance pathological outcomes. This could ultimately change the landscape of breast cancer treatment."
Additionally, Atossa is conducting a supplementary cohort within the I-SPY 2 study, targeting a 40 mg daily dose of (Z)-endoxifen, in various combinations, with interim data expected in the near future.
About (Z)-Endoxifen
(Z)-endoxifen functions as a selective estrogen receptor modulator (SERM), known for not only inhibiting but potentially degrading estrogen receptors. This treatment option has demonstrated efficacy against tumors resistant to standard endocrine therapies. Importantly, it addresses significant limitations posed by conventional treatments, such as minimal endometrial activity and enhanced bone-protective effects compared to tamoxifen.
Atossa’s innovative oral formulation of (Z)-endoxifen includes enteric coating designed to optimize absorption and effectiveness. Clinical trials have indicated it is well tolerated among participants, which is promising for ongoing and future studies.
Continuing Development and Innovation
Atossa Therapeutics is dedicated to treating metastatic breast cancer, a domain where fresh therapeutic strategies are pivotal. Currently, the company is involved in multiple Phase 2 trials for (Z)-endoxifen, including studies for ductal carcinoma in situ (DCIS) and various presentations of ER+/HER2- breast cancer. Their research endeavors are backed by a robust intellectual property portfolio, underscoring a commitment to innovation in breast cancer treatment.
About Atossa Therapeutics
Atossa Therapeutics, Inc. (NASDAQ: ATOS) strives to revolutionize breast cancer care through cutting-edge research and patient-centric solutions. The company’s flagship candidate, (Z)-endoxifen, aims at various stages of breast cancer management, from prevention to advanced treatment. Atossa is resolutely pushing forward with its clinical programs to enhance patient outcomes while ensuring lasting value for shareholders.
Frequently Asked Questions
What recent results has Atossa Therapeutics shared?
Atossa announced promising results from a study evaluating low-dose (Z)-endoxifen in treating ER+ breast cancer.
How effective was the treatment in the study?
The treatment resulted in significant tumor shrinkage and favorable Ki-67 suppression among participants.
What safety concerns were raised during the study?
The treatment was well tolerated, with mostly mild adverse events reported.
What are the future plans for (Z)-endoxifen?
Atossa plans to evaluate higher doses and combinations of (Z)-endoxifen in new trials.
What distinguishes (Z)-endoxifen from other treatments?
(Z)-endoxifen is noted for its targeted action and reduced side effects compared to traditional therapies like tamoxifen.
